Recent patents on anti-infective drug discovery最新文献

筛选
英文 中文
Effect of Low Dose Oral Vitamin-D and Calcium Replacement in HIV Patients. 低剂量口服维生素d和钙替代治疗HIV患者的效果。
Recent patents on anti-infective drug discovery Pub Date : 2016-03-31 DOI: 10.2174/1574891X11666160201122236
Satyajit Das, Shyamalie Bopitya, Ananya R Chowdhury, Archik Das, Huda Taha
{"title":"Effect of Low Dose Oral Vitamin-D and Calcium Replacement in HIV Patients.","authors":"Satyajit Das, Shyamalie Bopitya, Ananya R Chowdhury, Archik Das, Huda Taha","doi":"10.2174/1574891X11666160201122236","DOIUrl":"https://doi.org/10.2174/1574891X11666160201122236","url":null,"abstract":"BACKGROUND\u0000There is high prevalence of vitamin-D deficiency and abnormal bone mineral density (BMD) in HIV patients. Our aim is to find out the effect of replacement of low dose oral vitamin-D (800 International unit) with calcium (500mg) as a once daily regimen along with antiretroviral (ARV) on serum vitamin-D and parathyroid hormone (PTH) level and bone mineral density (BMD) changes on patients with HIV infection who have vitamin- D deficiency.\u0000\u0000\u0000METHODS\u0000This is a non-randomised, open label study. We collected information about demography, viral load, CD-4 count, fracture risk factors. We measured serum 25(OH)D, parathyroid hormone (intact PTH), inorganic phosphate, corrected calcium, alkaline phosphatase (ALP) and BMD of hip and spine at baseline and after 12 months of routine follow up. Patients were treatment experienced and were divided into tenofovir containing, efavirenz containing, and protease Inhibitor (PI) containing regimens.\u0000\u0000\u0000RESULTS\u0000The study included 87 treatment experienced HIV patients with mean age 42.8 (+/-7.8) years, 55 (63%) females, 73 (84%) black African ethnicity, CD4 count 451.7 (+/-184.6) cells/dL, plasma VL 1.6 log (+/-0.03) copies/mL, exposure to antiretroviral therapy 43.2 (+/-30.2) months and duration of illness 58.4 (+/- 24.1) months. Forty four patients agreed to take vitamin-D with calcium replacement and 43 patients did not agree to take the replacement. After 12 months of follow up patients on vitamin D and calcium replacement (n=44) had significant increase in vitamin-D level (15.4+/-6.2 vs. 55.9+/-22.6, p=0.0001), reduction in PTH (8.04 +/-7.5, vs. 4.7 +/-1.8, p=0.005), alkaline phosphatase (111.1 +/-79.1 vs. 90.2+/-42.2, p=0.038) and increase in corrected calcium (2.18 +/-0.09 vs. 2.19 +/-0.09 p=0.001). In patients not on vitamin-D replacement (n=43), there was increase in vitamin-D (16.9 +/-12.1 vs. 49.4 +/-29.2, p=0.001) and corrected calcium (2.12 +/-0.09 vs. 2.16 +/-0.08 p=0.0001) level, but PTH and ALP did not change. BMD of hip and spine did not show any significant change in either of the two groups. In multivariate analysis that included all significant variables, vitamin-D and calcium replacement independently was associated with increase in vitamin-D level (OR 1.07, CI 1.02, 1.12, p=0.005), decrease in PTH level (OR 0.53, CI 0.35, 0.82, p=0.004), but not with change in corrected calcium, alkaline phosphatase, BMD of hip or spine.\u0000\u0000\u0000CONCLUSION\u0000After 12 months of follow up, replacement of low dose once daily oral vitamin-D with calcium in treatment experienced HIV patients with vitamin-D deficiency can increase vitamin-D level, reduce PTH level without any change in BMD of hip and spine.","PeriodicalId":20909,"journal":{"name":"Recent patents on anti-infective drug discovery","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2016-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2174/1574891X11666160201122236","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67992729","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
The Antidiabetic Effects of The Bioactive Flavonoid (Kaempferol-3-O-β-D-6{P- Coumaroyl} Glucopyranoside) Isolated From Allium cepa. 大蒜生物活性类黄酮山奈酚-3- o -β- d -6{P-香豆醇}葡萄糖吡喃苷的抗糖尿病作用。
Recent patents on anti-infective drug discovery Pub Date : 2016-03-31 DOI: 10.2174/1574891X11666151105130233
Ogbonna J Ikechukwu, Ofoefule S Ifeanyi
{"title":"The Antidiabetic Effects of The Bioactive Flavonoid (Kaempferol-3-O-β-D-6{P- Coumaroyl} Glucopyranoside) Isolated From Allium cepa.","authors":"Ogbonna J Ikechukwu, Ofoefule S Ifeanyi","doi":"10.2174/1574891X11666151105130233","DOIUrl":"https://doi.org/10.2174/1574891X11666151105130233","url":null,"abstract":"BACKGROUND\u0000Allium cepa has been in use in traditional medicine in the treatment of diabetes mellitus. The aqueous and ethanolic extracts have been found effective in lowering blood glucose levels in experimental diabetic rats and guinea pigs.\u0000\u0000\u0000METHODS\u0000The study was carried out to isolate the active principle responsible for the observed hypoglycaemic effect in experimental animals. Freeze-dried aqueous extract of Allium cepa was separated into various fractions using column chromatography with silica gel as a stationary phase. The column was eluted with various ratios of mixtures of hexane, chloroform, ethyl acetate and methanol. These column fractions obtained were tested for hypoglycaemic effects in alloxan-induced diabetic male rats. The identified active fraction was further separated by means of preparative thin layer chromatography (P-TLC) using silica gel as stationary phase and mixture of solvents chloroform, ethyl acetate, and methanol in the ratio of 10: 4: 1 respectively as the mobile phase. Pre-coated P-TLC plates were used and the fraction bands were identified under u.v. lamp and by spraying with concentrated sulphuric acidvanillin reagent. The isolated bands (Rf 0.438) were scrapped off from the P-TLC plates, redissolved in absolute methanol, filtered and concentrated to dryness.\u0000\u0000\u0000RESULTS\u0000The isolated compound's structure was determined be means of one and two dimensional nuclear magnetic resonance spectroscopy as well as comparison with literature data. The isolated compound given at 25 mg/kg dose reduced blood glucose in diabetic rats in manner which was comparable to the effect obtained with 2 mg/kg of glibenclamide (p < 0.05). The structure of the compound was found to be that of kaempferol- 3-O-β - D 6{P-coumaroyl} glucopyranoside.\u0000\u0000\u0000CONCLUSION\u0000The research findings have supported the claims that extracts of Allium cepa possess glucose lowering properties in experimental diabetic animals.","PeriodicalId":20909,"journal":{"name":"Recent patents on anti-infective drug discovery","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2016-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2174/1574891X11666151105130233","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67992688","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 23
Detection of blaKPC and blaGES Carbapenemase Genes in Klebsiella pneumoniae Isolated from Hospitalized Patients in Kashan, Iran. 伊朗卡尚地区住院患者肺炎克雷伯菌blaKPC和blaGES碳青霉烯酶基因的检测
Recent patents on anti-infective drug discovery Pub Date : 2016-01-01 DOI: 10.2174/1574891X11666160813192556
Farzaneh Firoozeh, Mehdi Aghaseyed-Hosseini, Mohammad Zibaei, Ahmad Piroozmand
{"title":"Detection of blaKPC and blaGES Carbapenemase Genes in Klebsiella pneumoniae Isolated from Hospitalized Patients in Kashan, Iran.","authors":"Farzaneh Firoozeh,&nbsp;Mehdi Aghaseyed-Hosseini,&nbsp;Mohammad Zibaei,&nbsp;Ahmad Piroozmand","doi":"10.2174/1574891X11666160813192556","DOIUrl":"https://doi.org/10.2174/1574891X11666160813192556","url":null,"abstract":"<p><strong>Introduction: </strong>Klebsiella pneumoniae carbapenemase (KPC)-producing bacteria are among the highly antimicrobial resistant gram negative bacteria and infections due to them are an increasingly major health problem worldwide.</p><p><strong>Methods: </strong>In this study we have detected the blaKPC and blaGES carbapenemase genes in Klebsiella pneumoniae isolated from hospitalized patients in Kashan, Iran. In a cross-sectional study, a total of 181 K. pneumoniae isolates were recovered from clinical specimens during November 2013 to October 2014.</p><p><strong>Result: </strong>Antimicrobial susceptibility profiles were determined using disk diffusion method according to the European Committee on Antimicrobial Susceptibility Testing (EUCAST) and CLSI guidelines. Carbapenem-resistant K. pneumoniae isolates were identified. PCR method and sequencing were used for detection of blaKPC and blaGES carbapenemase genes. Of the 181 K. pneumoniae isolates, 35 (19.3%) were found to be resistant to imipenem and 150 (82.9%) were identified as MDR strains. Among carbapenems, the most resistant rate 39 (21.5%) was seen against ertapenem using disk diffusion method. Of K. pneumoniae isolates 21 (11.6%) and 42 (23.2%) carried blaKPC and blaGES genes, respectively and 19(10.5%) carried both genes simultaneously.</p><p><strong>Conclusion: </strong>The data of current study revealed that the frequency of resistance to carbapenems and production of carbapenemase enzymes especially GES type was high among clinical isolates of K pneumoniae in Kashan, Iran.</p>","PeriodicalId":20909,"journal":{"name":"Recent patents on anti-infective drug discovery","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2016-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34309726","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 8
Complement 3 Receptor Expression in Individuals with Type 2 Diabetes. 补体3受体在2型糖尿病患者中的表达
Recent patents on anti-infective drug discovery Pub Date : 2016-01-01 DOI: 10.2174/1574891X11666160608121617
Judy Ly, Devin Morris, Minette Lagman, Christopher Ng, Shelby Anderson, John Daliva, Naji Muwanas, Igal Tarash, Cesar Ochoa, Airani Sathananthan, Vishwanath Venketaraman
{"title":"Complement 3 Receptor Expression in Individuals with Type 2 Diabetes.","authors":"Judy Ly,&nbsp;Devin Morris,&nbsp;Minette Lagman,&nbsp;Christopher Ng,&nbsp;Shelby Anderson,&nbsp;John Daliva,&nbsp;Naji Muwanas,&nbsp;Igal Tarash,&nbsp;Cesar Ochoa,&nbsp;Airani Sathananthan,&nbsp;Vishwanath Venketaraman","doi":"10.2174/1574891X11666160608121617","DOIUrl":"https://doi.org/10.2174/1574891X11666160608121617","url":null,"abstract":"<p><strong>Background: </strong>According to the World Health Organization, as of 2014 9% of the world's adult population is affected by diabetes. Uncontrolled diabetes is a pro-inflammatory process that increases generation of reactive oxygen species (ROS).</p><p><strong>Methods: </strong>The production of ROS leads to a chronic increase in oxidative stress which results in an increased susceptibility to infections. Individuals with type 2 diabetes mellitus (T2DM) are highly susceptible to Mycobacterium tuberculosis (M. tb) infection. Previous research has demonstrated that glutathione (GSH) plays an important role in the control of M. tb infection. Recent studies have demonstrated that phagocytosis of M.tb is diminished in patients with T2DM. Phagocytosis in macrophages is thought to be mediated in part by complement protein 3b (C3b)-complement protein receptor 3b (C3R) interactions. Since C3b production is not diminished in patients with T2DM we propose that C3R production is reduced and is the cause for impaired macrophage phagocytosis as well as IL-12 and IFN-γ signaling.</p><p><strong>Conclusion: </strong>This study utilizes a quantitative PCR (qPCR), demonstrating decreased transcription of C3R mRNA in patients with T2DM as compared to non-diabetics.</p>","PeriodicalId":20909,"journal":{"name":"Recent patents on anti-infective drug discovery","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2016-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34472058","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Site Targeted Press Coated Delivery of Methylprednisolone Using Eudragit RS 100 and Chitosan for Treatment of Colitis. 用乌拉吉r100和壳聚糖靶向压迫递送甲基强的松龙治疗结肠炎。
Recent patents on anti-infective drug discovery Pub Date : 2016-01-01 DOI: 10.2174/1574891x10666150917115218
Swati Jagdale, Apoorva Chandekar
{"title":"Site Targeted Press Coated Delivery of Methylprednisolone Using Eudragit RS 100 and Chitosan for Treatment of Colitis.","authors":"Swati Jagdale,&nbsp;Apoorva Chandekar","doi":"10.2174/1574891x10666150917115218","DOIUrl":"https://doi.org/10.2174/1574891x10666150917115218","url":null,"abstract":"<p><strong>Background: </strong>Inflammatory bowel disease (IBD) is one of the five most prevalent gastrointestinal disease burdens which commonly require lifetime care. Worldwide incidence rate of ulcerative colitis and Crohn's disease is about 16.8% and 13.4% respectively. Colitis is an inflammation of the colon. Colon targeted drug delivery will direct the drug to the colon. The drug will reach at the site of action and hence its side effects as well as dose can be reduced. Recent patent describes treatment of ulcerative colitis using anti CD3 antibodies, with nicotine and anti-depressant drugs, budesonide foam etc.</p><p><strong>Objective: </strong>Present study deals with optimization of site targeted methylprednisolone delivery for treatment of colitis.</p><p><strong>Method: </strong>Chitosan and Eudragit RS 100 were used as coating polymers. Tablets were prepared by press coated technology. The core tablets contain drug, avicel as binder, croscarmellose sodium as super disintegrant and dicalcium phosphate as diluent. Drug excipient compatibility was carried out using FTIR, UV and DSC. Design of experiment was used to optimize the formulation. Tablets were evaluated for thickness, weight variation, hardness, swelling index, in-vitro drug release and release of drug in simulated media.</p><p><strong>Results: </strong>Optimized batch (B2) contained chitosan 40% and eudragit RS 100 17.5%. B2 showed in-vitro drug release 85.65 ± 7.6% in 6.8 pH phosphate buffer and 96.7 ±9.1% in simulated media after 7.5 hours.</p><p><strong>Conclusion: </strong>In-vivo x-ray placebo study for formulation B2 had shown that the tablet reached to the ascending colon after 5 hours. This indicated a potential site targeted delivery of optimized batch B2.</p>","PeriodicalId":20909,"journal":{"name":"Recent patents on anti-infective drug discovery","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2016-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2174/1574891x10666150917115218","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34182020","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Lipid-based Vesicular Nanocargoes as Nanotherapeutic Targets for the Effective Management of Rheumatoid Arthritis. 类风湿性关节炎的有效治疗靶点:脂质水疱纳米颗粒。
Recent patents on anti-infective drug discovery Pub Date : 2016-01-01 DOI: 10.2174/1574891x1101160511195513
Mahfoozur Rahman, Sarwar Beg, Gajanand Sharma, Sumant Saini, Rehan A Rub, Preeti Aneja, Firoz Anwar, Mohammad A Alam, Vikas Kumar
{"title":"Lipid-based Vesicular Nanocargoes as Nanotherapeutic Targets for the Effective Management of Rheumatoid Arthritis.","authors":"Mahfoozur Rahman,&nbsp;Sarwar Beg,&nbsp;Gajanand Sharma,&nbsp;Sumant Saini,&nbsp;Rehan A Rub,&nbsp;Preeti Aneja,&nbsp;Firoz Anwar,&nbsp;Mohammad A Alam,&nbsp;Vikas Kumar","doi":"10.2174/1574891x1101160511195513","DOIUrl":"https://doi.org/10.2174/1574891x1101160511195513","url":null,"abstract":"<p><strong>Background: </strong>Rheumatoid arthritis (RA) is an immune mediated joint-based chronic inflammatory disorder recognized by joint inflammation, destruction, pain and remission. Currently, numerous pharmacotherapeutic strategies have gained immense popularity in RA therapy and improving the patient life.</p><p><strong>Methods: </strong>Besides, it exhibits numerous drawbacks such as requirement of high dose of drugs, unavoidable adverse effects and diseases remission. Thus, use of currently available pharmacotherapeutics employing conventional formulations can only provide therapeutic effects to a certain extent.</p><p><strong>Results: </strong>Recent advancements in nanotechnology-based lipidic vesicular nanocarriers have led provided improved efficacy and safety for the anti-rheumatic drugs. These include liposomes, stealth liposomes, ethosomes, transfersomes, etc., which have shown their potential to improve the therapeutic efficacy of antirheumatic drugs with lesser toxicity. Although the results of animal models for use of lipid vesicular nanocarriers for drug targeting in RA have been found to be highly promising, but lack of sufficient data in a clinical setup are still evident to demonstrate their practical utility in patient populations. In this regard, considerable research studies are required for evaluating the efficacy and safety of the aforementioned nanocarriers in RA through clinical studies.</p><p><strong>Conclusion: </strong>The present review, therefore, covers the brief pathophysiology of RA, current medication and their challenges in RA therapy. Besides, an extensive account on recent advancements in novel lipid vesicular nanocarriers in RA therapy has also been addressed with special emphasis on the patent literature too.</p>","PeriodicalId":20909,"journal":{"name":"Recent patents on anti-infective drug discovery","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2016-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2174/1574891x1101160511195513","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34392158","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 12
Hybolites Revisited. Hybolites再访。
Recent patents on anti-infective drug discovery Pub Date : 2016-01-01 DOI: 10.2174/1574891x11666160406121706
V. Norris, Cécile Verrier, M. Feuilloley
{"title":"Hybolites Revisited.","authors":"V. Norris, Cécile Verrier, M. Feuilloley","doi":"10.2174/1574891x11666160406121706","DOIUrl":"https://doi.org/10.2174/1574891x11666160406121706","url":null,"abstract":"BACKGROUND Hyperstructures are large assemblies of molecules and macromolecules that perform functions such as metabolism (including RNA and protein synthesis and degradation), transport, DNA replication, cell division, signalling and chemotaxis. METHODS Such hyperstructures might be manipulated by hybrid metabolites or hybolites made by a pairwise, covalently linked combination of the thousands of small molecules involved in metabolism and signalling. RESULTS Here, we review recent evidence for hyperstructures in prokaryotes and for interactions between hyperstructures as a determinant of the phenotype. We also mention extending hybolite therapy to eukaryotes, consider new designs for hybolites, and discuss relevant patents.","PeriodicalId":20909,"journal":{"name":"Recent patents on anti-infective drug discovery","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2016-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2174/1574891x11666160406121706","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67992737","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Effect of Pistacia atlantica Fruit and Leaf Extracts on Hydatid Cyst Protoscolices. 大西洋木果叶提取物对包虫病原侧凸的影响。
Recent patents on anti-infective drug discovery Pub Date : 2016-01-01 DOI: 10.2174/1574891x10666151029113334
Mohammad Zibaei, Reza Rostamipour, Hassan Nayebzadeh
{"title":"Effect of Pistacia atlantica Fruit and Leaf Extracts on Hydatid Cyst Protoscolices.","authors":"Mohammad Zibaei,&nbsp;Reza Rostamipour,&nbsp;Hassan Nayebzadeh","doi":"10.2174/1574891x10666151029113334","DOIUrl":"https://doi.org/10.2174/1574891x10666151029113334","url":null,"abstract":"<p><strong>Background: </strong>Treatment of human hydatidosis is mainly surgical, with chemical treatment being reserved as a coadjuvant treatment. Use of effective protoscolicidal agents during surgery of hydatid disease is essential to reduce the recurrence rate.</p><p><strong>Objective: </strong>The aim of this study was to investigate the scolicidal effects of Pistacia atlantica leaf and fruit hydroalcoholic extracts on protoscolices of hydatid cyst.</p><p><strong>Method: </strong>Echinococcus granulosus protoscolices were obtained from 50 sheep infected with hydatid cysts. Various concentrations of plant hydroalcoholic extracts were used in different exposure times for viability assay of protoscolices.</p><p><strong>Results: </strong>The scolicidal effects of the hydroalcoholic extracts of the leaf, fresh and dried fruits were significant compared to the control groups (P < 0.05). Among the Pistacia atlantica extracts tested, 0.1% (mg/ml) concentrations of fresh fruit extract (99.09 ± 1.27) and leaf extract (89.25 ± 18.42) had strong scolicidal effects in 360 min, of exposure times and the mortality rate decreased with the lower concentration.</p><p><strong>Conclusion: </strong>Information from the current study has the strong scolicidal effect of fresh fruit hydroalcoholic extract of Pistacia atlantica on protoscoleces, which may be used as a scolicidal agent during the surgery techniques.</p>","PeriodicalId":20909,"journal":{"name":"Recent patents on anti-infective drug discovery","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2016-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2174/1574891x10666151029113334","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34192702","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 14
Correlation Between qacE and qacE∆1 Efflux Pump Genes, Antibiotic and Disinfectant Resistant Among Clinical Isolates of E.coli. 临床分离大肠杆菌qacE、qacE∆1外排泵基因与抗生素、消毒剂耐药性的相关性
Recent patents on anti-infective drug discovery Pub Date : 2016-01-01 DOI: 10.2174/1574891X11666160815094718
Maryam Shafaati, Mohammadali Boroumand, Jamileh Nowroozi, Pouya Amiri, Hossein Kazemian
{"title":"Correlation Between qacE and qacE∆1 Efflux Pump Genes, Antibiotic and Disinfectant Resistant Among Clinical Isolates of E.coli.","authors":"Maryam Shafaati,&nbsp;Mohammadali Boroumand,&nbsp;Jamileh Nowroozi,&nbsp;Pouya Amiri,&nbsp;Hossein Kazemian","doi":"10.2174/1574891X11666160815094718","DOIUrl":"https://doi.org/10.2174/1574891X11666160815094718","url":null,"abstract":"<p><strong>Introduction: </strong>Antiseptics and disinfectants have been used widely in hospitals and other health care settings to control the growth of microorganisms. However, some disinfectant resistant strains were reported. The objectives of our study were to evaluate correlation between the efflux pump genes, drugs and disinfectant resistant among clinical isolates of E.coli.</p><p><strong>Methods: </strong>A total of 102 of E. coli strains were isolated from urine sample of hospitalized patients. The antibiotic susceptibility was carried out by disc diffusion method. Didecyl di-methyl ammonium chloride (DDDMAC) was used as Quaternary ammonium compound (QAC) disinfectant which was used in Heart Center Hospital. PCR reaction was carried out for detection of qacE and qac∆E efflux pump genes.</p><p><strong>Result: </strong>Almost all the strains had higher resistance to ampicillin, ciproflaxacin, cotrimaxazole and cephalothin. Totally 49% (n: 50) of strains were produced ESBL. Almost all the strains have MIC value between 0.00195 to 0.0078 mg/l for DDDMAC. Correlation between presence of qacE and qac∆E genes and antibiotic resistance was perceived. Presence of qacE and qac∆E genes among strains that have high disinfectant MIC value were 96.9% and 93.7% respectively. In addition, 98% of ESBL producing strains harbored qacE gene and 94% of ESBL producing strains harbored qac∆E gene.</p><p><strong>Conclusion: </strong>Our study indicated that there was a strong correlation between presence of qacE and qac∆E genes with resistance to some antibiotics and growth in media which contain high concentration of disinfectant. In conclusion, other mechanisms also play important role in resistant to antimicrobial agents but the role of efflux pumps in resistant to antimicrobial agents should not be neglected.</p>","PeriodicalId":20909,"journal":{"name":"Recent patents on anti-infective drug discovery","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2016-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34309724","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 22
Methicillin-resistant Staphylococcus aureus: treatment with cultures of not drug-resistant Staphylocuccus epidermidis. 耐甲氧西林金黄色葡萄球菌:用不耐药的表皮葡萄球菌培养物进行治疗。
Felix-Martin Werner, Rafael Coveñas
{"title":"Methicillin-resistant Staphylococcus aureus: treatment with cultures of not drug-resistant Staphylocuccus epidermidis.","authors":"Felix-Martin Werner, Rafael Coveñas","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The colonization and infection with methicillin-resistant Staphylococcus aureus is a major health problem in hospitals and long-term care facilities. Although bacteriaemias with MRSA (methicillin-resistant Staphylococcus aureus) can be treated with vancomycin and other reserve antibiotics, 20% of patients cannot be successfully cured. Inpatients colonized with MRSA are isolated in hospitals according to the guidelines of the Robert-Koch-Institute, althouth in long-term care facilities these patients are not urgently isolated. Active decolonization measures are taken to eradicate colonization with MRSA. In order to reduce MRSA colonization, it could be possible to administer cultures of Staphylococcus epidermidis which have no anbitiotic resistance, so that physiological genes could be conferred from Staphylococcus epidermis to MRSA bacteria.</p>","PeriodicalId":20909,"journal":{"name":"Recent patents on anti-infective drug discovery","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2015-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34123396","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信